Treatment with systemic immunostimulatory agents (including but not limited to interferons or interleukin-) within  weeks or five half-lives of the drug, whichever is shorter, prior to randomization

Treatment with systemic immunosuppressive medications (including but not limited to interferons, IL-) within  days or  half-lives of the drug, whichever is longer, prior to randomization.

Treatment with systemic immunostimulatory agents (including but not limited to interferons or Interlukin- [IL-]) within  weeks or five half-lives of the drug (whichever is shorter) prior to randomization

Treatment with systemic immunostimulatory agents (including but not limited to interferons or IL-) within  weeks or five half-lives of the drug, whichever is shorter, from cycle  day .

Treatment with systemic immunostimulatory agents (including but not limited to interferons or interleukin [IL]-) within  weeks or five half-lives of the drug (whichever is longer) prior to randomisation

Treatment with systemic immunostimulatory agents (including but not limited to interferons or interleukin-) within  weeks or five half-lives of the drug, whichever is shorter, prior to enrollment

Interferons:  weeks

Treatment with systemic immunostimulatory agents (including but not limited to interferons or interleukin [IL]-) within  weeks or five half-lives of the drug, whichever is shorter

Treatment with systemic immunostimulatory agents (including but not limited to interferons or interleukin-) within  weeks or five half-lives of the drug, whichever is shorter, prior to enrollment

Treatment with systemic immunosuppressive medications (including but not limited to interferons, IL-) within  weeks or  half-lives of the drug, whichever is longer, prior to randomization

Patients treated with systemic immunostimulatory agents (such as interferons, IL ) within  weeks of the start of the treatment or  half-lives of the drug, whichever is shorter

Treatment with systemic immunostimulatory agents (including but not limited to interferons or interleukin  [IL-]) within  weeks or five drug elimination half-lives prior to Day  of Cycle , whichever is longer

Treatment with systemic immunostimulatory agents (including but not limited to interferons or IL-) within  weeks or five half-lives of the drug (whichever is shorter) prior to randomization